SCHEMBL6488031

SCHEMBL6488031

O=C(O)c1ccc(CN2C(=O)Nc3sc(C#CCc4ccccc4)nc3S2(=O)=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 5/20 0.41
SLC22A8 Q8TCC7 1/20 0.38
PTGER4 P35408 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC2 Q92769 2/20 0.35
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
PKM P14618 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RECQL P46063 1/20 0.34
PLEC Q15149 1/20 0.34
SAE1 Q9UBE0 1/20 0.34
UBA2 Q9UBT2 1/20 0.34
SLC6A3 Q01959 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
PPARG P37231 1/20 0.32
IDO1 P14902 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6259482 0.83 MMP13 (0.40) MMP13SLC22A8PTGER4HDAC1HDAC2
SCHEMBL6254860 0.77 MMP13 (0.39) MMP13SLC22A8PTGER4LMNAHPGD
SCHEMBL6477654 0.73 MMP13 (0.52) MMP13SLC22A8HDAC1HDAC2
SCHEMBL6234905 0.70 MMP13 (0.48) MMP13SLC22A8LMNAHPGDKDM4E
SCHEMBL6704154 0.67 MMP13 (0.39) MMP13SLC22A8PTGER4HDAC1LMNA
SCHEMBL6254249 0.67 MMP13 (0.39) MMP13SLC22A8PTGER4LMNAHPGD
SCHEMBL6448095 0.65 FFAR1 (0.44) MMP13SLC22A8HDAC1HDAC2
SCHEMBL6478451 0.64 MMP13 (0.44) MMP13SLC22A8HDAC1HDAC2HPGD
SCHEMBL6289378 0.64 MMP13 (0.38) MMP13SLC22A8HDAC1LMNAHPGD
SCHEMBL8355360 0.64 MMP13 (0.52) MMP13SLC22A8HDAC1HDAC2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849648-B2 Phenylene alkyne matrix metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-02-01 US disclosed
US-20040019055-A1 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib ROARK WILLIAM HOWARD (US) 2004-01-29 US disclosed
US-20030144274-A1 Alkyne matrix metalloproteinase inhibitors BUNKER AMY MAE (US) 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019055-A1 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib MMP13, MMP11, MMP10 MMP13 1/4885SLC22A8 155/4885PTGER4 116/4885
US-20030144274-A1 Alkyne matrix metalloproteinase inhibitors MMP11, MMP13, MMP3 MMP13 2/4885SLC22A8 1147/4885PTGER4 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.